BIOLASE (BIOL) Q3 2024 earnings summary

Executive summary

• Net revenue for Q3 2024 was $10.9M, nearly flat year-over-year; nine-month revenue declined 9% to $32.5M due to lower laser system sales, partially offset by higher consumables and services.

• Net loss narrowed to $1.4M for Q3 2024 from $4.6M in Q3 2023; nine-month net loss improved to $10.7M from $15.3M year-over-year.

• On October 1, 2024, BIOLASE and subsidiaries filed for Chapter 11 bankruptcy; operations continue as debtors-in-possession.

• MegaGen Implant Co., LTD won the auction to acquire substantially all assets for $20.5M, subject to court approval.

• Company delisted from Nasdaq in June 2024 and from OTCQB in October 2024; now trades on OTC Pink Market.

Financial highlights

• Gross profit margin improved to 40% in Q3 2024 from 34% in Q3 2023, driven by lower warranty, service, and freight costs.

• Operating expenses fell 32% year-over-year in Q3 2024, mainly from cost savings in sales, marketing, and G&A.

• Cash and cash equivalents were $3.4M at September 30, 2024, down from $6.6M at year-end 2023.

• Working capital deficit was $11.4M at September 30, 2024, compared to $5.2M working capital at December 31, 2023.

• Adjusted EBITDA for Q3 2024 was $(3.1)M, an improvement from $(6.0)M in Q3 2023.

Outlook and guidance

• Management expresses substantial doubt about the ability to continue as a going concern due to recurring losses, negative cash flow, and bankruptcy proceedings.

• Additional capital will be required; ability to raise funds is uncertain, especially after delisting from major exchanges.

• Company expects to continue operations during bankruptcy and pursue asset sale to MegaGen, pending court approval.